IL15 and neoplasm: Surprisingly, even after almost 3 weeks in vivo in the presence of K562 tumor cells and high doses of IL-15, iCD8α+ NK cells had enhanced responses to K562 and cytokine stimulation compared with persistent CD8α– or sustained CD8α+ NK cells.